[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.5.76. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Observation
April 2016

Omalizumab Treatment of Vernal Keratoconjunctivitis

Author Affiliations
  • 1Unit of Respiratory Medicine and Allergology, Department of Clinical and Experimental Medicine, Azienda Ospedaliero Universitaria Policlinico–Vittorio Emanuele Hospital, University of Catania, Catania, Italy
JAMA Ophthalmol. 2016;134(4):461-463. doi:10.1001/jamaophthalmol.2015.5679

Vernal keratoconjunctivitis (VKC) is a severe ocular, chronic, relapsing disease that can result in loss of visual acuity and blindness. Treatment with topical antihistamines, mast-cell stabilizers, corticosteroids, or even topical immunosuppressors (ie, cyclosporine or tacrolimus) frequently does not improve VKC symptoms, and partial control of symptoms with oral corticosteroids can induce severe adverse events with long-term use.1 Omalizumab is a humanized monoclonal antibody directed toward IgE and is approved for treating severe allergic asthma and severe chronic idiopathic urticaria.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×